USFDA completes inspection at Solara Active Pharma Sciences’ Mangalore facility
The Agency has issued an EIR on November 18, 2025 and determined that the inspection classification of the facility is VAI and concluded this inspection as closed
Solara Active Pharma Sciences (Solara) has successfully completed the inspection carried out by the US Food and Drug Administration (USFDA) between August 25 and August 29, 2025 at Mangalore facility, Karnataka. The Agency has issued an EIR (Establishment Inspection Report) on November 18, 2025 and determined that the inspection classification of the facility is ‘Voluntary Action Indicated (VAI)’ and concluded this inspection as closed.
Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.
